Category : Search result: H1 FY26


Hvax Technologies H1 FY26 Income Jumps 35%

Hvax Technologies announces impressive 35% growth in total income for H1 FY26, reaching ₹5.95 crore. The company shows strong financial performance with significant profit improvements.

Shivashrit Foods H1 FY26 Revenue Grows 20%

Shivashrit Foods Limited achieves impressive 20% YoY revenue growth and 22% PAT increase in H1 FY26, showcasing strong operational efficiency and market performance.

RDB Infrastructure stock jumps 7% after Q2 results

RDB Infrastructure & Power shares surged 7% as Q2 FY26 net profit jumped 79% YoY to ₹3.05 crore. EBITDA margins expanded significantly to 26.3% despite revenue decline. Stock has delivered 718% returns in 2 years.

Chamunda Electrical H1 FY26 PAT Jumps 332% YoY

Chamunda Electrical reports stellar H1 FY26 performance with 332% PAT surge and 28% revenue growth. Strong order book signals continued expansion in electrical equipment sector.

Hindustan Copper Q2 profit jumps 85% to ₹186 crore

State-owned Hindustan Copper reports impressive 85% surge in Q2 FY26 net profit reaching ₹186.02 crore, driven by robust income growth. Discover the key financial highlights and operational insights.

Standard Glass Lining Stock Gains 3.2%

Standard Glass Lining stock surged 3.2% as Indian markets extended gains. The company's Q2 FY26 profit rose 8.5% to ₹8.68 crore. Read more for key insights.

Subex Q2 FY26: Revenue Rises, Profit Declines 78%

Subex Limited reports mixed Q2 FY26 results with revenue growth of 3.78% YoY to ₹6,891 lakhs but profit after tax plunges 78%. Normalized EBITDA shows operational improvement. Read full analysis.

Mitsu Chem Plast Q2 Profit Jumps 66%

Mitsu Chem Plast Limited reports outstanding Q2 FY26 results with 66% net profit growth and 11% revenue increase, showcasing robust financial health and operational excellence.

Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook

Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.

Page 1 of 3